Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By sjmartinez • August 16, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. PMID: 37364283.

Tags: COPD, dual PDE3 and PDE4 inhibitor, ensifentrine, nebulized therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

The search for the ultra-elusive: Can computed cardiopulmonography enhance early detection of gas exchange abnormality?

Rossiter HB, Molgat-Seon Y. The search for the ultra-elusive: Can computed cardiopulmonography enhance early detection of gas exchange abnormality? Exp Physiol. 2025 Jun 17. doi:[...]

Pearls and Pitfalls of Intrathecal Amphotericin B Therapy for Refractory Coccidioidal Meningitis in Children: An Illustrative Pediatric Case Series

Malhotra S, Adachi K, Fallah A, Johnson R, Ishminder Kaur, McCarty J, Ross L, Krogstad P. Pearls and Pitfalls of Intrathecal Amphotericin B Therapy for[...]

Baseline Cardiac Biomarker Levels as Predictors of Cancer Risk in the MESA Cohort

Cai X, White Q, Johnson WC, Hansen SL, Dardari ZA, Blaha M, Michos ED, Lima JA, deFilippi CR, Budoff MJ, Watson KE, McClelland RL, Yang[...]